ALOGLIPTIN
Tracking # 20-811707
$99999.00
There are no ratings for this course
Learn more Educator STATPEARLS PUBLISHING, LLC
CE Broker Reporting Reported automatically
Method Computer-Based Training
Course overview
ALOGLIPTIN WAS FIRST APPROVED BY THE FDA IN JANUARY 2013 AND IS INDICATED TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM). IT IS A DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR USED TO IMPROVE GLYCEMIC CONTROL IN CONJUNCTION WITH DIET AND EXERCISE. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM, PHARMACOLOGY, CONTRAINDICATIONS, AND ADVERSE EVENTS ASSOCIATED WITH ALOGLIPTIN DRUG THERAPY.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Specialty Medical Practitioner
1h
General Medicine
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
1h
Category I CME
Mississippi State Board of Medical Licensure
Medical Doctor
1h
AMA Category I
Physician Assistant
1h
AMA Category I
State Medical Board of Ohio
Doctor of Medicine
1h
AMA Category I